美国Genentech公司宣称已能在哺乳动物细胞中合成AIDS重组蛋白.这种蛋白gp120是AIDS病毒HTLV-Ⅲ或LAV囊膜的一部分,它是优先考虑的AIDS疫苗的候选物.Genentech公司的中国仓鼠卵巢细胞能糖基化和分泌这种蛋白.作为一种疫苗,gp120的功效还需证明.1～2年后,猴试验可提供与人体应答相关的数据. Genentech, a U.S.-based company that claims to have been able to synthesise AIDS-recombinant proteins in mammalian cells, is part of the AIDS virus HTLV-III or LAV envelope and is a candidate for a priority AIDS vaccine. Genentech’s Chinese hamster ovary Cells are able to glycosylate and secrete this protein, and as a vaccine, the efficacy of gp120 needs to be demonstrated, and 1 to 2 years later, the monkey test can provide data on human responses.